BIO CEO 2012 Fireside Chat With Mikael Dolsten

  • Recommend
  • Tweet
  • Print
  • Email

Tuesday, February 14th, 8:00am-8:45am

 

Mikael Dolsten, MD, PhD
President, Worldwide Research and Development, Pfizer Inc.

Mikael Dolsten is the President of Worldwide Research and Development, advancing Pfizer's leadership in small molecule science and medicines, as well as its leadership, expertise, and innovation in the areas of biotherapeutics and vaccines. Worldwide R&D combines entrepreneurial Biotech Units with core platforms; Research Units with deep disease area expertise; and broad multi disciplinary scientific expertise to discover innovative therapeutic programs in biotherapeutics, vaccines and small molecules. Mikael is also co-chair of the company's Portfolio Strategy and Investment (PSI) Committee, which governs major pipeline investments and strategic R&D priorities.

Pfizer scientists across WRD apply industry-leading scientific and technological expertise across a range of small molecule and biologic platforms and modalities. In a global network of research laboratories and clinical study sites, Pfizer R&D professionals and business unit colleagues focus on translating deep science into safe and effective drugs to prevent, treat and cure disease.

Mikael oversees all Pfizer research units and biotech units in PharmaTherapeutics and BioTherapeutics: Antibacterials; Cardiovascular, Metabolic & Endocrine Diseases; Internal Medicine; Neuroscience; Oncology; Pain & Sensory Disorders; Regenerative Medicine; Indications Discovery; Inflammation & Immunology; Orphan & Genetic Diseases; Center for Therapeutic Innovation; Vaccine R&D; CovX; Rinat; and Oligonucleotide Therapeutics.

Moderator:

Mark Schoenebaum, Senior Biotechnology Analyst, ISI Group
ISI’s Health Care Research Team, headed by Mark Schoenebaum, focuses on providing actionable investment ideas and proprietary research on Biotechnology, Pharmaceutical, and Specialty Pharmaceutical stocks.  Mark has been conducting research on biotechnology companies for more than 10 years. Mark and his team provide clients with an investment edge through “data tidbits” and “on-the-fly” analysis in response to breaking news. They also provide "deep-dive" analyses on clinical, financial, and market data.  The Health Care Research Team is available around the clock, conducts customized client projects, assists with corporate access, and accepts personal meetings.